Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

23,577 signal articles · 332 in last 24h · 112,361 total before filter · latest 2h ago
332last 24h
2139last 7d
374● bullish (7d)
188● bearish (7d)
204publishers
AllMacro295Earnings1215M&A90Regulatory23Product13Analyst20
✕ clear all filtersticker: CVSsentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
Pharmacy giant closes more stores across U.S. in 2026
TheStreet1d agoneutral
Pharmacy giant closes more stores across U.S. in 2026

After closing hundreds of locations in recent years, a pharmacy giant is continuing to shrink its retail footprint, with more stores disappearing from communities across the U.S. The latest closures come as the chain works to reshape its business and focus on locations it believes have a stronger ...

Fluent Q2 Earnings Call Highlights
MarketBeat2d agoneutral
Fluent Q2 Earnings Call Highlights

Fluent (NASDAQ:FLNT) reported second-quarter 2026 revenue growth as its Commerce Media Solutions business expanded sharply and became a larger share of the company’s overall mix. Management said the quarter marked a milestone in the company’s strategic shift toward commerce media, while maintaining

CVS Health Q2 Earnings Call Highlights
MarketBeat6d agoneutral
CVS Health Q2 Earnings Call Highlights

CVS Health (NYSE:CVS) reported second-quarter results that exceeded its expectations, citing earnings growth across all operating segments and raising its full-year outlook for adjusted earnings per share and operating cash flow. Chair and Chief Executive Officer David Joyner said the company gener

CVS Stock Down On Early Warnings About 2027
The Wall Street Journal7d agoneutral
CVS Stock Down On Early Warnings About 2027

CVS Health saw its shares dip about 6% even though it handily beat Wall Street’s expectations for the most recent quarter and raised its guidance for 2026 earnings. The issue was the company’s unusually early commentary about 2027.

CVS’s Turnaround Faces Its Next Test
Barrons.com8d agoneutral
CVS’s Turnaround Faces Its Next Test

CVS Health reports earnings Wednesday, with analysts expecting another solid quarter and looking for potential guidance upside from its Aetna insurance and Caremark pharmacy-benefit businesses.

Bloomberg16d agoneutral
Morgan Stanley’s Wilson Says AI Adoption Key to Profit Outlook

(Bloomberg) -- US companies that are integrating artificial intelligence capabilities are well positioned this earnings season as they’re poised for stronger profit margins, according to Morgan Stanley strategists.Most Read from BloombergDeepSeek Suspends Fundraising After Viral US-China PostsUS, Iran Extend Pause in Strikes as Oman Holds Hormuz TalksSpaceX at $100 Would Imply Zero AI Value, Morgan Stanley SaysChina Chipmaker CXMT Jumps 466% in Debut After Blockbuster IPOStocks, Bonds Rise in Re

CVS Group Q4 Earnings Call Highlights
MarketBeat20d agoneutral
CVS Group Q4 Earnings Call Highlights

CVS Group (LON:CVSG) said revenue for the financial year ended June 30 exceeded GBP 710 million, up 5.9% from the prior year, as the veterinary services provider used an investor presentation to reiterate its capital allocation policy and outline expected returns from acquisitions and capital invest

In the Weight-Loss Wars, Novo’s Obesity Pill Is Pulling Way Ahead of Lilly’s
The Wall Street Journal29d agoneutral
In the Weight-Loss Wars, Novo’s Obesity Pill Is Pulling Way Ahead of Lilly’s

Since its obesity pill Foundayo hit the market in April, Lilly has captured about 11% of the prescription volume for new pills, according to the latest weekly data. Novo Nordisk’s Wegovy pill, which launched in January, commands the rest. It is a remarkable turn of events for the near $80 billion anti-obesity market, among the hottest in the industry.

FTC Reaches Settlement With CVS Health Over Insulin Prices
Barrons.com29d agoneutral
FTC Reaches Settlement With CVS Health Over Insulin Prices

The Federal Trade Commission announced a settlement with CVS Health’s pharmacy benefit manager business on Tuesday, the agency’s second major agreement this year with drug industry middlemen. Pharmacy-benefit managers, or PBMs, play a key role in negotiating with drug companies and selecting which prescription drugs will be covered by an insurance plan. In litigation filed in 2024 during the Biden administration, the commission alleged that rebates and fees collected by major PBMs from drug manufacturers artificially inflated the price of insulin.

Elevance and UnitedHealth Earnings Are Next Test for Hot Health Insurer Stocks
Barrons.com31d agoneutral
Elevance and UnitedHealth Earnings Are Next Test for Hot Health Insurer Stocks

After a rocky start to the year, health insurer stocks have roared back. The insurers are trying to end a difficult cycle that began about three years ago, when healthcare use, and the costs to cover it, accelerated postpandemic. The fund’s top 10 holdings encompass six health insurers, three of which— UnitedHealth Group Aetna parent CVS Health and Elevance Health —comprise more than 40% of the fund.

Bloomberg48d agoneutral
Nike Joins Alphabet, Walmart in Hiring a CFO From the Outside

(Bloomberg) -- Moving from Pfizer Inc. to Nike Inc. may seem like an unusual career shift for a finance chief. For David Denton, it marks a return to the consumer sector after four years in pharmaceuticals.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetGrand Ole Opry House Up For Sale by Owner Ryman HospitalityMicron Shares Soar After AI-Fueled Forecast Shatters ProjectionsStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapStocks Erase Gains a

Closed Rite Aid stores get surprising retail replacement
TheStreet60d agoneutral
Closed Rite Aid stores get surprising retail replacement

When Rite Aid, a major pharmacy retailer, filed for Chapter 11 bankruptcy a second time in 2025, it led to the shuttering of its 1,250 locations. Over time, many were sold to competitors like CVS and Walgreens, and some spaces were taken up by retailers such as Kroger and Albertsons. But some ...

CVS Health (CVS): Buy, Sell, or Hold Post Q1 Earnings?
StockStory61d agoneutral
CVS Health (CVS): Buy, Sell, or Hold Post Q1 Earnings?

Over the past six months, CVS Health has been a great trade, beating the S&P 500 by 20%. Its stock price has climbed to $100.39, representing a healthy 26.4% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.